Associate Professor Helen Irving

Pre-Eminent Specialist and Clinical Lead
Children's Health Queensland

Dr Irving is the Clinical Lead of the Centre for Children’s Health Ethics and Law (CCHEL)Children’s Health Queensland (CHQ). Her clinical role is, Pre-Eminent Specialist, Paediatric and Adolescent Oncology and Medical Lead for the Queensland Paediatric Haematology, Oncology and Palliative Care Network. Additionally, she is the Children’s Oncology Group (COG) CHQ site, Principal Investigator, past president of ANZCHOG and holds current membership of the International Neuroblastoma Risk Group (INRG), Advances in Neuroblastoma Research (ANR)group and the European neuroblastoma (SIOPEN) group. Her interest in bioethics stems from the challenges of care and decision making in paediatrics, particularly around extent of and conflict around care, clinical trial and drug access and research ethics. Dr Irving has previously, and is currently a member of a HREC. In addition she is an active Steering Committee member of the COG Bioethics Committee.

What does the conference theme “Do More” mean to you?
“Do More” does not always mean that “More (treatment) is Better”, however, when there is clear evidence of therapeutic benefit with newer agents, then more must be done to achieve equity of access.

Why are you excited about participating in MM2017?
The management of medicines in general is a critically important public health and individual responsibility. The Medicines Management Conference is an opportunity for strategic discussion, and information sharing between hospital pharmacists and prescribers. Challenges experienced by both professional groups can be examined with the aim to optimise responsible drug development, delivery and promotion.

Where do you see pharmacy in 10 years?
The future of pharmacy is exciting with greater emphasis of More appropriate drug use; targeted and personalised medicine and hopefully less treatment when there is little or no prospect of benefit.